Peringatan Keamanan

The oral LD50 in rats is >2g/kg and in mice is 1600mg/kg.L8651 The oral TDLO in rats is 9mg/kg.L8651

Treat patients with supportive care including monitoring of vital signs and observing clinical status.L8588,L8591 Recent overdose may be treated with inducing vomiting or gastric lavage.L8588,L8591 Due to fenofibrate's extensive protein binding, hemodialysis is not expected to be useful.A185936,L8588,L8591

Fenofibrate

DB01039

small molecule approved

Deskripsi

Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil.A185954 Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.L8588,L8591

Fenofibrate was granted FDA approval on 31 December 1993.L8585

Struktur Molekul 2D

Berat 360.831
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Fenofibric acid, the active metabolite of fenofibrate, has a half life of 23 hours.[L8588,L8591] Fenofibrate has a half life of 19-27 hours in healthy subjects and up to 143 hours in patients with renal failure.[A36366]
Volume Distribusi The volume of distribution of fenofibrate is 0.89L/kg,[A185954] and can be as high as 60L.[A36366]
Klirens (Clearance) The oral clearance of fenofibrate is 1.1L/h in young adults and 1.2L/h in the elderly.[L8588,L8591]

Absorpsi

A single 300mg oral dose of fenofibrate reaches a Cmax of 6-9.5mg/L with a Tmax of 4-6h in healthy, fasting volunteers.A185954

Metabolisme

Fenofibrate is completely hydrolyzed by liver carboxylesterase 1 to fenofibric acid.A185972,L8588,L8591 Fenofibric acid is either glucuronidated or has its carbonyl group reduced to a benzhydrol that is then glucuronidated.L8588,L8591 Glucuronidation of fenofibrate metabolites is mediated by UGT1A9.A17495 Reduction of the carbonyl group is primarily mediated by CBR1 and minorly by AKR1C1, AKR1C2, AKR1C3, and AKR1B1.A185984

Rute Eliminasi

5-25% of a dose of fenofibrate is eliminated in the feces, while 60-88% is eliminated in the urine.A185936,L8588,L8591 70-75% of the dose recovered in the urine is in the form of fenofibryl glucuronide and 16% as fenofibric acid.A185936

Interaksi Makanan

1 Data
  • 1. Take with food. Bioavailability is increased 2- to 3-fold when taken with food.

Interaksi Obat

1373 Data
Troglitazone Troglitazone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Reserpine Reserpine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Progesterone Progesterone may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Chlorpromazine Chlorpromazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Cimetidine Cimetidine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Bosentan Bosentan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Glyburide Glyburide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fusidic acid Fusidic acid may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Simeprevir Simeprevir may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Lenvatinib Lenvatinib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Letermovir The metabolism of Fenofibrate can be decreased when combined with Letermovir.
Valinomycin Valinomycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Celecoxib Celecoxib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Erythromycin The serum concentration of Fenofibrate can be increased when it is combined with Erythromycin.
Olmesartan Olmesartan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Pralsetinib Pralsetinib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Phenytoin The metabolism of Fenofibrate can be increased when combined with Phenytoin.
Fosphenytoin The metabolism of Fenofibrate can be increased when combined with Fosphenytoin.
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Fenofibrate.
Clofibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Fenofibrate.
Gemfibrozil The risk or severity of adverse effects can be increased when Fenofibrate is combined with Gemfibrozil.
Bezafibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Bezafibrate.
Etofibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Etofibrate.
Ciprofibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Ciprofibrate.
Simfibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Simfibrate.
Ronifibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Ronifibrate.
Aluminium clofibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Aluminium clofibrate.
Clofibride The risk or severity of adverse effects can be increased when Fenofibrate is combined with Clofibride.
Fenofibric acid The risk or severity of adverse effects can be increased when Fenofibrate is combined with Fenofibric acid.
Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Fenofibrate.
Glycochenodeoxycholic Acid The therapeutic efficacy of Glycochenodeoxycholic Acid can be decreased when used in combination with Fenofibrate.
Cholic Acid The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Fenofibrate.
Glycocholic acid The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Fenofibrate.
Deoxycholic acid The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Fenofibrate.
Taurocholic acid The therapeutic efficacy of Taurocholic acid can be decreased when used in combination with Fenofibrate.
Obeticholic acid The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Fenofibrate.
Chenodeoxycholic acid The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Fenofibrate.
Taurochenodeoxycholic acid The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Fenofibrate.
Tauroursodeoxycholic acid The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Fenofibrate.
Bamet-UD2 The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Fenofibrate.
Dehydrocholic acid The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Fenofibrate.
Hyodeoxycholic Acid The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Fenofibrate.
Ursodeoxycholic acid The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibrate.
Cyclosporine The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibrate.
Glimepiride The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glimepiride.
Acetohexamide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Acetohexamide.
Chlorpropamide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Chlorpropamide.
Tolazamide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Tolazamide.
Glipizide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glipizide.
Gliclazide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Gliclazide.
Tolbutamide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Tolbutamide.
Gliquidone The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Gliquidone.
Glisoxepide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glisoxepide.
Glibornuride The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glibornuride.
Carbutamide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Carbutamide.
Metahexamide The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Metahexamide.
Colestipol Colestipol can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colesevelam Colesevelam can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholestyramine Cholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Phenindione The risk or severity of bleeding can be increased when Fenofibrate is combined with Phenindione.
Coumarin The risk or severity of bleeding can be increased when Fenofibrate is combined with Coumarin.
(R)-warfarin The risk or severity of bleeding can be increased when Fenofibrate is combined with (R)-warfarin.
Tioclomarol The risk or severity of bleeding can be increased when Fenofibrate is combined with Tioclomarol.
(S)-Warfarin The risk or severity of bleeding can be increased when Fenofibrate is combined with (S)-Warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Fenofibrate is combined with Ethyl biscoumacetate.
Diphenadione The risk or severity of bleeding can be increased when Fenofibrate is combined with Diphenadione.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Fenofibrate is combined with 4-hydroxycoumarin.
Clorindione The risk or severity of bleeding can be increased when Fenofibrate is combined with Clorindione.
Tacrolimus Tacrolimus may increase the nephrotoxic activities of Fenofibrate.
Nafcillin The metabolism of Fenofibrate can be increased when combined with Nafcillin.
Modafinil The metabolism of Fenofibrate can be increased when combined with Modafinil.
Avasimibe The metabolism of Fenofibrate can be increased when combined with Avasimibe.
Echinacea The metabolism of Fenofibrate can be increased when combined with Echinacea.
Dexamethasone acetate The metabolism of Fenofibrate can be increased when combined with Dexamethasone acetate.
Cerivastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Cerivastatin.
Fluvastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Fluvastatin.
Mevastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Mevastatin.
Pitavastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Pitavastatin.
Pitolisant The serum concentration of Fenofibrate can be decreased when it is combined with Pitolisant.
Atenolol Atenolol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Atropine Atropine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fluorescein Fluorescein may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Telmisartan Telmisartan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Prasterone sulfate Fenofibrate may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.
Indocyanine green acid form Fenofibrate may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.
Benzbromarone Fenofibrate may decrease the excretion rate of Benzbromarone which could result in a higher serum level.
Pilsicainide Fenofibrate may decrease the excretion rate of Pilsicainide which could result in a higher serum level.
Glycyrrhizic acid Fenofibrate may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.
Diclofenac Diclofenac may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Naproxen Naproxen may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Cefaclor Cefaclor may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Tinidazole Tinidazole may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Repaglinide Repaglinide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Disulfiram Disulfiram may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Nitrendipine Fenofibrate may decrease the excretion rate of Nitrendipine which could result in a higher serum level.
Ranolazine Ranolazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Nicardipine The metabolism of Fenofibrate can be decreased when combined with Nicardipine.
Atorvastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Atorvastatin.

Target Protein

Peroxisome proliferator-activated receptor alpha PPARA
Nuclear receptor subfamily 1 group I member 2 NR1I2
Matrix metalloproteinase-25 MMP25

Referensi & Sumber

Synthesis reference: Jean-Francois Boyer, "Medicine based on fenofibrate, and a method of preparing it." U.S. Patent US4800079, issued January, 1988.
Artikel (PubMed)
  • PMID: 27594083
    Wei X, Li P, Liu M, Du Y, Wang M, Zhang J, Wang J, Liu H, Liu X: Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2017 Apr;31(4). doi: 10.1002/bmc.3832. Epub 2016 Oct 10.
  • PMID: 3318449
    Chapman MJ: Pharmacology of fenofibrate. Am J Med. 1987 Nov 27;83(5B):21-5. doi: 10.1016/0002-9343(87)90867-9.
  • PMID: 9515185
    Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. doi: 10.2165/00003088-199834020-00003.
  • PMID: 2226216
    Balfour JA, McTavish D, Heel RC: Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990 Aug;40(2):260-90. doi: 10.2165/00003495-199040020-00007.
  • PMID: 12582161
    Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B: The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83. Epub 2003 Feb 11.
  • PMID: 23386599
    Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB: The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013 Feb;33(2):210-22. doi: 10.1002/phar.1194.
  • PMID: 27599626
    Malatkova P, Kanavi M, Nobilis M, Wsol V: In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. doi: 10.1016/j.cbi.2016.09.001. Epub 2016 Sep 4.
  • PMID: 19251819
    Liu A, Patterson AD, Yang Z, Zhang X, Liu W, Qiu F, Sun H, Krausz KW, Idle JR, Gonzalez FJ, Dai R: Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. Drug Metab Dispos. 2009 Jun;37(6):1157-63. doi: 10.1124/dmd.108.025817. Epub 2009 Feb 27.
Menampilkan 8 dari 9 artikel.

Contoh Produk & Brand

Produk: 516 • International brands: 4
Produk
  • Aa-feno-micro
    Capsule • 200 mg • Oral • Canada • Generic • Approved
  • Aa-feno-micro
    Capsule • 67 mg • Oral • Canada • Generic • Approved
  • Aa-feno-super
    Tablet • 100 mg • Oral • Canada • Generic • Approved
  • Aa-feno-super
    Tablet • 160 mg • Oral • Canada • Generic • Approved
  • Aa-feno-super
    Tablet • 200 mg • Oral • Canada • Generic • Approved
  • Antara
    Capsule • 43 mg/1 • Oral • US • Approved
  • Antara
    Capsule • 130 mg/1 • Oral • US • Approved
  • Antara
    Capsule • 130 mg/1 • Oral • US • Approved
Menampilkan 8 dari 516 produk.
International Brands
  • Fenogal — SMB Laboratories
  • Lipanthyl — Abbott
  • Lipantil
  • Lipidil — lbirn

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul